This company listing is no longer active
Melodiol Global Health Past Earnings Performance
Past criteria checks 0/6
Melodiol Global Health's earnings have been declining at an average annual rate of -17.7%, while the Pharmaceuticals industry saw earnings growing at 35.4% annually. Revenues have been growing at an average rate of 45.6% per year.
Key information
-17.7%
Earnings growth rate
43.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 45.6% |
| Return on equity | n/a |
| Net Margin | -187.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Melodiol Global Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 19 | -36 | 14 | 0 |
| 30 Jun 23 | 12 | -54 | 19 | 0 |
| 31 Mar 23 | 10 | -43 | 18 | 0 |
| 31 Dec 22 | 6 | -22 | 13 | 0 |
| 30 Sep 22 | 8 | -25 | 18 | 0 |
| 30 Jun 22 | 8 | -18 | 18 | 0 |
| 31 Mar 22 | 7 | -24 | 23 | 0 |
| 31 Dec 21 | 6 | -30 | 27 | 0 |
| 30 Sep 21 | 5 | -31 | 24 | 0 |
| 30 Jun 21 | 4 | -32 | 21 | 0 |
| 31 Mar 21 | 3 | -32 | 15 | 0 |
| 31 Dec 20 | 2 | -31 | 10 | 0 |
| 30 Sep 20 | 3 | -29 | 10 | 0 |
| 30 Jun 20 | 4 | -26 | 10 | 0 |
| 31 Mar 20 | 4 | -21 | 11 | 0 |
| 31 Dec 19 | 4 | -15 | 11 | 0 |
| 30 Sep 19 | 2 | -15 | 12 | 0 |
| 30 Jun 19 | 1 | -15 | 13 | 0 |
| 31 Mar 19 | 1 | -16 | 15 | 0 |
| 31 Dec 18 | 1 | -17 | 16 | 0 |
| 30 Sep 18 | 0 | -18 | 17 | 1 |
| 30 Jun 18 | 0 | -19 | 18 | 1 |
| 31 Mar 18 | 0 | -17 | 15 | 1 |
| 31 Dec 17 | 0 | -15 | 13 | 1 |
| 30 Sep 17 | 0 | -11 | 10 | 1 |
| 30 Jun 17 | 0 | -8 | 6 | 1 |
| 31 Mar 17 | 0 | -6 | 5 | 1 |
| 31 Dec 16 | 0 | -5 | 4 | 0 |
| 31 Dec 15 | 0 | 0 | 0 | 0 |
| 31 Dec 14 | 0 | 0 | 0 | 0 |
Quality Earnings: ME1 is currently unprofitable.
Growing Profit Margin: ME1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ME1 is unprofitable, and losses have increased over the past 5 years at a rate of 17.7% per year.
Accelerating Growth: Unable to compare ME1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ME1 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (46.5%).
Return on Equity
High ROE: ME1's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.